Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Verastem Inc. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 3 distinct art units. This structure indicates a moderately complex prosecution landscape with some concentration of work. The fact that there are 5 pending actions but only 4 distinct examiners suggests that at least one examiner is handling multiple matters, which can allow for more consistent negotiations on related technical issues.
SAHAR JAVANMARD is the busiest examiner for this portfolio, responsible for 2 busiest examiner pending actions. This represents a significant portion of the 5 pending office actions currently active. The use of 3 distinct art units and 4 distinct examiners suggests that while some matters are grouped, the company is still navigating multiple technical classifications. Practitioners should focus on the 2 pending actions with the busiest examiner to potentially find efficiencies in the prosecution of those related filings within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JAVANMARD, SAHAR | 2 | 64.8% | +34.1% |
| ARCORIA, PAUL JOSEPH | 1 | — | — |
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18704267 | METHODS OF TREATING ABNORMAL CELL GROWTH | ARCORIA, PAUL JOSEPH | — |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 142d overdue |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | — |
| 17989006 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH | JAVANMARD, SAHAR | — |
| 17921509 | METHODS OF TREATING ABNORMAL CELL GROWTH | HIRAKIS, SOPHIA P | — |
| Art Unit | Apps |
|---|---|
| 1622 | 2 |
| 1629 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704267 | METHODS OF TREATING ABNORMAL CELL GROWTH | ARCORIA, PAUL JOSEPH | — | §103§112 | Non-Final OA | — | Pending | Apr 24, 2024 |
| 18263820 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | SEITZ, ANTHONY JOSEPH | 1629 | §102§103 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 18085792 | THERAPEUTIC COMPOSITIONS, COMBINATIONS, AND METHODS OF USE | JAVANMARD, SAHAR | 1622 | §103§112Other | Final Rejection | 142d overdue | Pending | Dec 21, 2022 |
| 17989006 | METHODS AND COMPOSITIONS FOR TREATING ABNORMAL CELL GROWTH | JAVANMARD, SAHAR | 1622 | §103§112DP | Final Rejection | — | Pending | Nov 17, 2022 |
| 17921509 | METHODS OF TREATING ABNORMAL CELL GROWTH | HIRAKIS, SOPHIA P | 1623 | §103 | Non-Final OA | — | Pending | Oct 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial